Información del artículo
El Texto completo está disponible en PDF
References
[1.]
S. Wild, G. Roglic, A. Green, R. Sicree, H. King.
Global prevalence of diabetes: estimates for the year 2000 and projections for 2030.
Diabetes Care, 27 (2004), pp. 1047-1053
[2.]
P.W. Franks, J.L. Mesa, A.H. Harding, N.J. Wareham.
Gene-lifestyle interaction on risk of type 2 diabetes.
Nutr Metab Cardiovasc Dis, 17 (2007), pp. 104-124
[3.]
A.H. Mokdad, E.S. Ford, B.A. Bowman, D.E. Nelson, M.M. Engelgau, F. Vinicor, et al.
Diabetes trends in the US: 1990-1998.
Diabetes Care, 23 (2000), pp. 1278-1283
[4.]
E.L. González, S. Johansson, M.A. Wallander, L.A. Rodríguez.
Trends in the prevalence and incidence of diabetes in the UK: 1996-2005.
J Epidemiol Community Health, 63 (2009), pp. 332-336
[5.]
A. Green, H. Støvring, M. Andersen, H. Beck-Nielsen.
The epidemic of type 2 diabetes is a statistical artefact.
Diabetologia, 48 (2005), pp. 1456-1458
[6.]
N.J. Wareham, N.G. Forouhi.
Is there really an epidemic of diabetes?.
Diabetologia, 48 (2005), pp. 1454-1455
[7.]
D.W. Dunstan, P.Z. Zimmet, T.A. Welborn, M.P. De Courten, A.J. Cameron, R.A. Sicree, et al.
The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study.
Diabetes Care, 25 (2002), pp. 829-834
[8.]
H. Keen, R.J. Jarrett, P. McCartney.
The ten-year follow-up of the Bedford survey (1962-1972): glucose tolerance and diabetes.
Diabetologia, 22 (1982), pp. 73-78
[9.]
D.R. Williams, N.J. Wareham, D.C. Brown, C.D. Byrne, P.M. Clark, B.D. Cox, et al.
Undiagnosed glucose intolerance in the community: the Isle of Ely Diabetes Project.
Diabet Med, 12 (1995), pp. 30-35
[10.]
Centers for Disease Control and Prevention (CDC).
Trends in the prevalence and incidence of self-reported diabetes mellitus – United States, 1980-1994.
MMWR Morb Mortal Wkly Rep, 46 (1997), pp. 1014-1018
[11.]
C.M. Balion, P.S. Raina, H.C. Gerstein, P.L. Santaguida, K.M. Morrison, L. Booker, et al.
Reproducibility of impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) classification: a systematic review.
Clin Chem Lab Med, 45 (2007), pp. 1180-1185
[12.]
J. Tuomilehto, J. Lindström, J.G. Eriksson, T.T. Valle, H. Hämäläinen, P. Ilanne-Parikka, Finnish Diabetes Prevention Study Group, et al.
Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.
N Engl J Med, 344 (2001), pp. 1343-1350
[13.]
N.G. Forouhi, J. Luan, S. Hennings, N.J. Wareham.
Incidence of Type 2 diabetes in England and its association with baseline impaired fasting glucose: the Ely study 1990-2000.
Diabet Med, 24 (2007), pp. 200-207
[14.]
K.T. Khaw, N. Wareham, S. Bingham, R. Luben, A. Welch, N. Day.
Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk.
Ann Intern Med, 141 (2004), pp. 413-420
[15.]
T.Y. Wong, G. Liew, R.J. Tapp, M.I. Schmidt, J.J. Wang, P. Mitchell, et al.
Relation between fasting glucose and retinopathy for diagnosis of diabetes: three population-based cross-sectional studies.
Lancet, 371 (2008), pp. 736-743
[16.]
G.A. Rose.
The strategy of preventive medicine.
Oxford Medical Publications, (1994),
Copyright © 2009. Sociedad Española de Endocrinología y Nutrición
